Healthpeak Properties reported quarterly funds from operations (FFO) of $0.47 per share for Q4 2025, surpassing the consensus estimate of $0.46 per share and matching last year’s result. The company highlighted year-over-year same-store net operating income growth across its life science and medical office portfolios, driven by strong lease renewals and increased occupancy in key markets such as Boston and San Diego. Management noted that non-GAAP metrics, reconciled in the Form 8-K filed with the SEC, continue to support its portfolio repositioning strategy.

During the earnings call, Healthpeak reiterated its ongoing portfolio reshaping plan, which includes the spin-off of senior housing assets into a newly created externally managed vehicle, Janus Living. This transaction, expected to close in mid-2026, will separate roughly 100 senior housing properties representing approximately 15% of consolidated revenues. Proceeds from the spin-off will be redeployed into higher-growth life science assets, where Healthpeak projects annualized cash yields of 6%–8%.

Healthpeak maintains a well-covered dividend yielding approximately 7%, supported by a payout ratio near 70% of recurring FFO. Despite this attractive yield, the shares trade at a 15%–20% discount to net asset value (NAV), reflecting concerns over capital allocation and execution. The company’s total leverage ratio remains near 5.5x net debt to adjusted EBITDA, in line with peer averages but above its long-term target of 5.0x.

Analysts have downgraded Healthpeak to HOLD, citing the complexity of its dual-CEO structure and external management arrangements for Janus Living as significant execution risks. Since the end of 2019, Healthpeak’s total return has underperformed the Vanguard Real Estate ETF by nearly 60%, driven by capital allocation missteps and slower than expected FFO growth. Management has committed to enhanced governance measures and quarterly progress updates to address investor concerns over strategic execution.